ALPK3 Knockout HAP1 Polyclonal Cells provide a robust CRISPR/Cas9-edited polyclonal knockout cell population for interrogating the function of ALPK3, a serine/threonine-protein kinase crucial for cardiac muscle development. The polyclonal knockout format, generated via CRISPR/Cas9-mediated gene disruption, yields a heterogeneous pool of cells each carrying loss-of-function mutations in the ALPK3 gene, enabling population-level studies of gene ablation effects without single-cell cloning. This model serves as an accessible system to analyze the kinase’s role in sarcomere organization and cardiomyocyte differentiation, offering a genetically defined platform to dissect disease-relevant signaling pathways and test therapeutic interventions.
The host HAP1 cell line is a near-haploid chronic myeloid leukemia (CML) model derived from a male patient, characterized by a stable near-haploid karyotype that simplifies genetic manipulation and functional genomics studies. Its myeloid lineage background provides a baseline context for examining kinase signaling, while its haploid nature eliminates the complexity of diploid gene redundancy, making it an ideal chassis for generating clean knockout models. HAP1 cells are particularly suited for assays requiring unambiguous genotype-phenotype correlations, such as phospho-signaling analyses and drug response profiling, and their rapid proliferation facilitates high-throughput screening campaigns.
ALPK3 functions as a regulatory kinase within the sarcomere assembly and cardiac development pathways, phosphorylating key sarcomeric proteins including myosin regulatory light chain and cardiac troponin I to modulate contractile machinery and cardiomyocyte maturation. Its activity is transcriptionally governed by cardiac master regulators such as GATA4, NKX2-5, and MEF2C, and the kinase physically interacts with structural components like alpha-actinin, myomesin, and titin, positioning it at a critical node linking transcriptional programs to sarcomeric architecture. Loss of ALPK3 kinase function disrupts these phosphorylation events, leading to aberrant sarcomere organization and impaired cardiac muscle performance??hallmarks of autosomal recessive cardiomyopathy and congenital heart defects.
Although HAP1 cells are of hematopoietic origin rather than cardiac, this model remains highly relevant for mechanistic dissection of ALPK3 signaling due to its facile genetic tractability and conserved kinase-substrate relationships. The haploid background allows researchers to study ALPK3-dependent phosphorylation cascades and downstream effectors in a simplified system, where compensatory mechanisms from a second allele are absent. By combining this knockout pool with ectopic expression of cardiac transcription factors, investigators can reconstitute aspects of the cardiomyocyte differentiation program and assess ALPK3’s role in sarcomere biogenesis, bridging myeloid cell context with cardiac biology.
Key research applications include investigating the molecular basis of cardiomyopathy through phospho-signaling analysis and imaging-based sarcomere assembly assays, as well as conducting small-molecule screens to identify compounds that rescue ALPK3-deficient phenotypes. The polyclonal knockout cells are compatible with western blotting for target validation, immunofluorescence for sarcomeric protein localization, cardiac differentiation protocols to model developmental processes, and cell viability assays in the context of cardiac stress. For detailed technical support or to discuss your project, contact Ascent Research.
